Anticoagulation and Pain Management

Anticoagulation Therapy

• The European Society of Cardiology recommends Warfarin with an INR target of 2.0-3.0, especially in patients with mitral stenosis, although this may not apply to patients who have already undergone surgery 1
• The American College of Cardiology recommends Apixaban 5 mg twice daily (or 2.5 mg twice daily in patients with certain characteristics) as a first-line treatment 2
• Direct oral anticoagulants (DOACs) are recommended as the preferred first-line therapy for stroke prevention in patients with non-valvular atrial fibrillation, while warfarin remains the only option for patients with mechanical heart valves or moderate-to-severe mitral stenosis 3
• The CHA₂DS₂-VASc score should be calculated to determine the need for anticoagulation, with a score ≥2 in men or ≥3 in women indicating a strong indication for anticoagulation, and a score 0 in men or 1 in women indicating that anticoagulation is generally not recommended 4, 5, 6, 7, 8
• The following risk categories and recommended therapies are suggested:

6

• DOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) are the first choice for anticoagulation, with specific recommendations based on patient characteristics, such as prior gastrointestinal bleeding, high stroke risk, or high bleeding risk 3
• Apixaban should be dosed at 5mg twice daily (2.5mg twice daily if ≥2 of: age ≥80, weight ≤60kg, creatinine ≥1.5mg/dL) 9
• Dabigatran should be dosed at 150mg twice daily (110mg twice daily where available for patients ≥80 years or high bleeding risk) 3
• Edoxaban should be dosed at 60mg once daily (30mg once daily if weight ≤60kg, CrCl 15-50mL/min, or certain P-gp inhibitors) 9
• Rivaroxaban should be dosed at 20mg once daily with food (15mg once daily if CrCl 15-50mL/min) 9
• Warfarin should be used as a second choice for anticoagulation, with a target INR of 2.0-3.0, and regular INR monitoring (weekly during initiation, monthly when stable) 4
• The SAMe-TT2R2 score can be used to identify patients likely to achieve good INR control, and if Time in Therapeutic Range (TTR) <65%, measures should be implemented to improve control or switch to DOAC 3

Pain Management and Anticoagulation Interactions

• The American College of Cardiology advises against the use of NSAIDs, such as ibuprofen, in anticoagulated patients due to the increased risk of bleeding, and also notes that NSAIDs can worsen hypertension and renal function 2
• The American Academy of Orthopaedic Surgeons also warns against the use of NSAIDs in anticoagulated patients, citing the increased risk of bleeding 10
• Avoid combining antiplatelet therapy with anticoagulation unless absolutely necessary, as this significantly increases bleeding risk, as warned by the European Heart Journal 11

Anticoagulation in Specific Clinical Scenarios

• For atrial fibrillation >48 hours or unknown duration, therapeutic anticoagulation should be administered for at least 3 weeks before cardioversion, and continued for at least 4 weeks after successful cardioversion 3
• Long-term anticoagulation decisions should be based on the CHA₂DS₂-VASc score, not the success of cardioversion 3
• Double therapy (OAC plus P2Y12 inhibitor) should be administered immediately after hospital discharge for most patients, and triple therapy (adding aspirin) should be considered for a limited period (e.g., 1 month) only in patients at high ischemic and low bleeding risk 9
• For patients with hemorrhagic stroke and atrial fibrillation, anticoagulation should be delayed for 4-8 weeks after the bleeding event, with resumption only after the cause of bleeding has been addressed and repeat brain imaging confirms resolution of hemorrhage, as recommended by the European Society of Cardiology 12
• Consider left atrial appendage closure as an alternative in patients at very high risk of recurrent hemorrhage, according to the American Heart Association 13

Contraindications and Special Considerations

• Mechanical heart valves, moderate to severe mitral stenosis, severe renal impairment, and active pathological bleeding are contraindications for certain anticoagulants 6
• Advanced age is both a stroke risk factor and indication for anticoagulation, not a contraindication 6
• Temporarily interrupting anticoagulation for treatment of underlying conditions is recommended, according to the European Heart Journal 14
• For procedures requiring interruption >1 week in high-risk patients, consider bridging with unfractionated heparin or LMWH, as suggested by the American Heart Association in Circulation 15
• Regular reevaluation of stroke and bleeding risks is recommended, and the American College of Cardiology suggests reassessing anticoagulation need 5

Rate Control in Atrial Fibrillation

• The American College of Cardiology recommends beta-blockers as first-line agents for rate control in atrial fibrillation, with a Class I recommendation, and suggests considering titration of beta-blockers to achieve adequate heart rate control, with a target heart rate at rest of 60-80 bpm and during moderate exercise less than 110 bpm 16, 4
• The American College of Cardiology suggests evaluating heart rate response both at rest and during exercise, and considering combination therapy with digoxin if beta-blocker alone is insufficient, with a Class IIa recommendation 16